Matching articles for "TNKase"
In Brief: A New Indication for Tenecteplase (TNKase)
The tissue plasminogen activator (tPA) tenecteplase ( TNKase – Genentech) has been approved by the FDA for treatment of acute ischemic stroke in adults. It is the second tPA to be approved in the US for this…
Med Lett Drugs Ther. 2025 Apr 28; 67(1727):71-2 doi:10.58347/tml.2025.1727d
The tissue plasminogen activator (tPA) tenecteplase ( TNKase – Genentech) has been approved by the FDA for treatment of acute ischemic stroke in adults. It is the second tPA to be approved in the US for this indication; alteplase (Activase) was approved in 1996. Tenecteplase was approved in 2000 to reduce the risk of death associated with acute ST-elevation myocardial infarction (STEMI).
Tenecteplase (TNKase) for Thrombolysis
Tenecteplase, a recombinant variant of human tissue plasminogen activator, is now available for thrombolysis in patients with acute myocardial infarction.
Med Lett Drugs Ther. 2000 Nov 13; 42(1092):106-8
Tenecteplase, a recombinant variant of human tissue plasminogen activator, is now available for thrombolysis in patients with acute myocardial infarction.
